Our study indicates that miR-300 is downregulated in response to ET-1; miR-300 reportedly suppresses tumor formation in human glioblastoma, making it an attractive candidate biomarker for the prediction of response to cancer treatment [42, 43]. Here, EDN1 is linked to glioblastoma.